Literature DB >> 10790089

Use of clindamycin disks To detect macrolide resistance mediated by ermB and mefE in Streptococcus pneumoniae isolates from adults and children.

K Waites1, C Johnson, B Gray, K Edwards, M Crain, W Benjamin.   

Abstract

We studied 198 macrolide-resistant S. pneumoniae isolates obtained from adults and children to evaluate whether 2-microgram clindamycin disks can distinguish between isolates manifesting ermB- versus mefE-mediated resistance to clarithromycin and to determine the relative frequency with which each resistance mechanism occurred in these populations. The mefE gene was predominant among 109 isolates from children, occurring in 73.4% versus 50.6% of 89 isolates from adults. Three isolates (1.5%) did not amplify either gene. Among 125 mefE(+) isolates, the MIC of clarithromycin at which 90% of the isolates tested were inhibited, determined by Etest, was 32 microgram/ml versus >256 microgram/ml in 70 ermB(+) isolates. All ermB(+) isolates were highly resistant to clindamycin (MICs >256 microgram/ml), whereas all mefE(+) isolates were susceptible to clindamycin using the 2-microgram disk. Testing S. pneumoniae from the respiratory tract for susceptibility to clindamycin by agar disk diffusion is an easy and inexpensive method to estimate the frequency of resistance mediated by ermB in specific patient populations. Macrolide resistance mediated by ermB is usually of greater magnitude than that due to mefE. Clinical studies are needed to determine the significance of high- versus low-level macrolide resistance in S. pneumoniae.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10790089      PMCID: PMC86572     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  17 in total

1.  Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995.

Authors:  V D Shortridge; G V Doern; A B Brueggemann; J M Beyer; R K Flamm
Journal:  Clin Infect Dis       Date:  1999-11       Impact factor: 9.079

Review 2.  Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria.

Authors:  R Leclercq; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

Review 3.  Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification.

Authors:  R Leclercq; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

4.  Detection of erythromycin resistance by the polymerase chain reaction using primers in conserved regions of erm rRNA methylase genes.

Authors:  M Arthur; C Molinas; C Mabilat; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

5.  Antipneumococcal activities of levofloxacin and clarithromycin as determined by agar dilution, microdilution, E-test, and disk diffusion methodologies.

Authors:  C L Clark; M R Jacobs; P C Appelbaum
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

6.  In vitro activities of oral antimicrobial agents against penicillin-resistant Streptococcus pneumoniae: implications for outpatient treatment.

Authors:  K Waites; E Swiatlo; B Gray; E Brookings
Journal:  South Med J       Date:  1997-06       Impact factor: 0.954

7.  Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin.

Authors:  K B Patel; D Xuan; P R Tessier; J H Russomanno; R Quintiliani; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

8.  Distribution of mefE and ermB genes in macrolide-resistant strains of Streptococcus pneumoniae and their variable susceptibility to various antibiotics.

Authors:  T Nishijima; Y Saito; A Aoki; M Toriya; Y Toyonaga; R Fujii
Journal:  J Antimicrob Chemother       Date:  1999-05       Impact factor: 5.790

9.  mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae.

Authors:  A Tait-Kamradt; J Clancy; M Cronan; F Dib-Hajj; L Wondrack; W Yuan; J Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

10.  Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system.

Authors:  J Sutcliffe; A Tait-Kamradt; L Wondrack
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

View more
  15 in total

1.  Mechanisms of macrolide resistance in clinical pneumococcal isolates in France.

Authors:  F Fitoussi; C Doit; P Geslin; N Brahimi; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.

Authors:  G V Doern; K P Heilmann; H K Huynh; P R Rhomberg; S L Coffman; A B Brueggemann
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae.

Authors:  James H Jorgensen; Sharon A Crawford; M Leticia McElmeel; Cynthia G Whitney
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

Review 4.  Molecular detection of the macrolide efflux gene: to discriminate or not to discriminate between mef(A) and mef(E).

Authors:  Corné H W Klaassen; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides.

Authors:  D J Hoban; A K Wierzbowski; K Nichol; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

6.  β-Lactam resistance, serotype distribution, and genotypes of meningitis-causing Streptococcus pneumoniae, Rio de Janeiro, Brazil.

Authors:  David E Barroso; Daniel Godoy; Terezinha M P P Castiñeiras; Mary M Tulenko; Maria C Rebelo; Lee H Harrison
Journal:  Pediatr Infect Dis J       Date:  2012-01       Impact factor: 2.129

7.  Dissemination of macrolide-resistant Streptococcus pneumoniae isolates containing both erm(B) and mef(A) in South Korea.

Authors:  Ken B Waites; Kellie E Jones; Kyung Hyo Kim; Stephen A Moser; Crystal N Johnson; Susan K Hollingshead; Eun-Suk Kang; Ki Sook Hong; William H Benjamin
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

8.  Resistance of group B streptococcus to selected antibiotics, including erythromycin and clindamycin.

Authors:  Judith S Heelan; Meredith E Hasenbein; Alexander J McAdam
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

Review 9.  Resistance to macrolide, lincosamide, streptogramin, ketolide, and oxazolidinone antibiotics.

Authors:  Marilyn C Roberts
Journal:  Mol Biotechnol       Date:  2004-09       Impact factor: 2.695

10.  In vitro activities of cethromycin (ABT-773), a new ketolide, against Streptococcus pneumoniae strains that are not susceptible to penicillin or macrolides.

Authors:  Edward O Mason; Linda B Lamberth; Ellen R Wald; John S Bradley; William J Barson; Sheldon L Kaplan
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.